Communiqués Altamira Therapeutics Nasdaq

Actions

CYTO

BMG0360L2099

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 07/06/2024			Varia. 5j.	Varia. 1 janv.
1,43 ^USD	-4,03 %		-6,54 %	-58,91 %

16/05	Altamira Therapeutics Ltd. élit Dominik Lysek comme membre du conseil d'administration	CI
01/05	Altamira Therapeutics Ltd. annonce le dépôt d'une demande de brevet provisoire pour des nanoparticules OligoPhore avec siRNA ciblant la protéine p65 dans le traitement du cancer et de l'inflammation	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Altamira Therapeutics Provides Business Update	28/05	AQ
Altamira Therapeutics Announces Dissemination of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis Through Social Media Channels of Top Allergy Journal	23/05	AQ
Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation	01/05	AQ
Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal	24/04	AQ
Altamira Therapeutics : Notice of the Annual General Meeting of Shareholders of Altamira Therapeutics Ltd. (the “Company”) to be held on May 16, 2024 - Form 6-K	16/04	PU
Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial Results	10/04	AQ
Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024	04/04	AQ
Altamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA Vaccines	25/03	AQ
Altamira Therapeutics’ Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed Journal	07/02	AQ
Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment	24/01	AQ
Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics Summit	08/01	AQ
Altamira Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement	29/12	AQ
Altamira Therapeutics : Corporate Presentation Winter 2023	20/12	PU
Altamira Therapeutics : Reverse Share Split - Form 6-K	11/12	PU
Altamira Therapeutics Provides Investor and Business Update	11/12	AQ
Altamira Therapeutics : Warrant Inducement Agreement - Form 6-K	08/12	PU
Altamira Therapeutics to Host Investor & Business Update Call on December 11th	05/12	AQ
Altamira Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement	29/11	AQ
Altamira Therapeutics : Compliance with Continued Listing Rule - Form 6-K	22/11	PU
Altamira Therapeutics Announces Partial Spin-Off of Bentrio® Business	17/11	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Altamira Therapeutics Nasdaq

Actions

CYTO

BMG0360L2099

Communiqués

Filtres